Compare CVS Health Corp (CVS) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs HSBC Holdings plc — how do they compare? CVS Health Corp trades at $85.88 (market cap $112.29B), while HSBC Holdings plc trades at $92.61 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 2.8× CVS Health Corp's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and HSBC Holdings plc for 36 Days on average.
| CVS | HSBC | |
|---|---|---|
Market Cap | $112.29B | $311.92B |
Volume | 7,763,676 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $110.60 | $107.86 |
52-Week Low | $70.08 | $65.67 |
Typical Hold Time | 83 Days | 36 Days |
Enterprise Value | $174.64B | $222.19B |
Dividend Yield | 3.03% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
HSBC trades at $93.71, down 3.97% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and recent earnings beats in two of the last three quarters. Recent developments include expansion in technology banking and wealth management services, while analyst consensus leans toward Hold with 52.38% of ratings.
The outlook remains mixed with strong profitability metrics offset by bearish technical indicators and negative net cash flow. Key opportunities include wealth management growth and strategic hires, while risks involve CFO transition and competitive pressures. The stock's valuation appears reasonable but requires monitoring of cash flow trends and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
